Vancouver-based psychedelic extraction and drug discovery company Filament Health has entered into a co-development and exclusive licensing agreement with Kelowna-based psychedelic therapy company Entheotech Bioscience.
According to the agreement, both parties will jointly develop psychedelic drug candidates, leveraging Entheotech’s proprietary spore library and Filament’s drug development platform. Filament will also license its botanical psilocybin drug candidate PEX010 to be used in two of Entheotech’s clinical trials for chronic pain and depression.
The partnership makes Filament eligible to receive a consideration of CAD 525,000 (USD 415,375) from Entheotech upon achievement of certain milestones.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.